Vaccine. 2014 Oct 8. pii: S0264-410X(14)01303-6. doi: 10.1016/j.vaccine.2014.09.035. [Epub ahead of print]
The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).
Chen RT1, Carbery B2, Mac L3, Berns KI4, Chapman L3, Condit RC4, Excler JL5, Gurwith M6, Hendry M3, Khan AS7, Khuri-Bulos N8, Klug B9, Robertson JS10,Seligman S11, Sheets R12, Williamson AL13; for the V3SWG.
Recombinant viral vectors provide an effective means for heterologous antigen expression in vivo and thus represent promising platforms for developing novel vaccines against human pathogens from Ebola to tuberculosis. An increasing number of candidate viral vector vaccines are entering human clinical trials. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to improve our ability to anticipate potential safety issues and meaningfully assess or interpret safety data, thereby facilitating greater public acceptance when licensed.
Published by Elsevier Ltd.
Immunization; Safety; Vaccines; Viral Vector
- [PubMed - as supplied by publisher]